Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on ...

Bicycle Therapeutics plc , a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the ...

An oral presentation will feature ALLO-316, an investigational AlloCAR T product targeting CD70. ALLO-316 is currently being studied in patients with advanced or metastatic renal cell carcinoma (RCC).

Company's first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammationNovel ...

Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel, targeted, small molecule cancer therapeutics, today announced that a Trial in Progress poster for its first-in-human, ...

Title: ZW1528, a Bispecific Antibody Targeting IL-4Ra and IL-33, Potently Inhibits Key Mediators of Airway Inflammation ...

BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the poster presentation ...

Nagpur: The National Service Scheme of Nagpur University and Jankalyankari Samiti Nagpur will be jointly organizing Vidarbha ...

Finance Income, net was $1.0 million for the three months ended March 31, 2025, compared to $0.7 million in the same period ...